Target Price | $10.00 |
Price | $1.74 |
Potential |
474.71%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Milestone Pharmaceuticals, Inc. 2026 .
The average Milestone Pharmaceuticals, Inc. target price is $10.00.
This is
474.71%
register free of charge
$25.00
1,336.78%
register free of charge
$2.00
14.94%
register free of charge
|
|
A rating was issued by 5 analysts: 4 Analysts recommend Milestone Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Milestone Pharmaceuticals, Inc. stock has an average upside potential 2026 of
474.71%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.39 | -0.64 |
0.72% | 53.96% | |
P/E | negative |
2 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast for earnings per share. The average Milestone Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Milestone Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 27 2025 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 14 2024 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Aug 22 2024 |
Rodman & Renshaw | Locked ➜ Locked | Locked | Aug 22 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 27 2025 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 14 2024 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Aug 22 2024 |
Locked
Rodman & Renshaw: Locked ➜ Locked
|
Aug 22 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.